



This is a repository copy of *Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique*.

White Rose Research Online URL for this paper:  
<http://eprints.whiterose.ac.uk/152536/>

Version: Accepted Version

---

**Article:**

Arden-Close, E., Pacey, A. [orcid.org/0000-0002-4387-8871](http://orcid.org/0000-0002-4387-8871) and Eiser, C. (2010) Health-related quality of life in survivors of lymphoma: a systematic review and methodological critique. *Leukemia & Lymphoma* , 51 (4). pp. 628-640. ISSN 1042-8194

<https://doi.org/10.3109/10428191003587263>

---

This is an Accepted Manuscript of an article published by Taylor & Francis in *Leukemia & Lymphoma* on 02/06/2010, available online:  
<http://www.tandfonline.com/10.3109/10428191003587263>.

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>



**Health related quality of life (HRQoL) in survivors of lymphoma: A systematic review and methodological critique**

Journal:	<i>Leukemia and Lymphoma</i>
Manuscript ID:	GLAL-2009-0694.R1
Manuscript Type:	Review
Date Submitted by the Author:	18-Dec-2009
Complete List of Authors:	Arden-Close, Emily Pacey, Allan Eiser, Christine
Keywords:	Lymphoma and Hodgkin disease < Neoplasia, health-related quality of life, survivorship



W Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Health related quality of life (HRQoL) in survivors of lymphoma: A systematic review and methodological critique**

**Running title: Quality of life in lymphoma survivors: review**

E Arden-Close<sup>1</sup>, A Pacey<sup>2</sup>, & C Eiser<sup>1</sup>

<sup>1</sup> Department of Psychology, University of Sheffield

<sup>2</sup> Academic Unit of Reproductive and Developmental Medicine, School of Medicine and Biomedical Sciences, University of Sheffield

**Author for Correspondence:** Emily Arden-Close

**Address** Department of Psychology  
University of Sheffield  
Western Bank  
Sheffield  
S10 2TP

**Tel:** 00 44 114 222 6583

**E-mail:** [e.arden-close@sheffield.ac.uk](mailto:e.arden-close@sheffield.ac.uk)

**Keywords:** Lymphoma and Hodgkin Disease, Health-related quality of life, survivorship

1  
2  
3 ABSTRACT  
4

5 Survival rates for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma have  
6 improved in recent years. However, these improvements are associated with various  
7 late effects, which can compromise health-related quality of life (HRQoL).  
8

9 Improving HRQoL is a significant goal in oncology, and increasingly one of the  
10 primary outcomes in clinical trials, but is dependent on availability of reliable and  
11 sensitive measures. This review therefore aimed to: (i) identify and evaluate  
12 commonly used HRQoL measures; (ii) compare HRQoL in lymphoma patients with  
13 the general population; and assess the association between (iii) HRQoL and different  
14 treatments; and (iv) HRQoL and demographic, medical and psychological variables.  
15

16 Standardized systematic searches identified 18 eligible studies that included adult  
17 survivors of lymphoma and reported quantitative results by histological diagnosis.  
18 Information about design, sample, measures and findings was extracted from each  
19 study. Survivors of lymphoma experienced worse physical but comparable mental  
20 HRQoL to the general population. No conclusions could be drawn about the  
21 association between different treatments and HRQoL. Correlates of better HRQoL  
22 included younger age, educational level, being employed, male gender, earlier stage  
23 disease, not having co-morbid illnesses, and meeting public health exercise  
24 guidelines. Limitations of current research relating to research design, sample  
25 demographics and reporting of descriptive statistics were identified. Given the  
26 increasing numbers of patients living with lymphoma, controlled studies using  
27 appropriate measures are required to determine the HRQoL consequences associated  
28 with the condition.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

The lymphomas [Hodgkin's Lymphoma (HL)] and Non-Hodgkin's Lymphoma (NHL)] are among the most common cancers to affect individuals of all ages although NHL tends to be more common in older people [1]. Survival rates for both cancers have improved rapidly, and current five-year survival rates of 87% for HL [2] and 65% for NHL [3] have been reported. However, physical late effects, including cardiac dysfunction, secondary malignancies, neuro-cognitive impairment and gonadal dysfunction have been identified [4]. Such effects may compromise health-related quality of life (HRQoL). This is typically defined as a multidimensional concept covering all aspects of well-being, including physical functioning (ability to carry out everyday physical activities), mental functioning (emotional functioning), social functioning (ability to interact in the usual way in society) and role functioning (involvement in life situations related to work, household chores, and family life) [5]. Improving HRQoL is a significant goal in oncology, and increasingly one of the primary outcomes in clinical trials [6].

HRQoL has been assessed in survivors of HL and NHL in a number of studies, but the evidence has not been reviewed systematically. Such a review would facilitate understanding of long-term HRQoL among lymphoma survivors and the extent to which it may be influenced by medical, demographic and psychosocial factors. This information could in turn enable healthcare professionals to provide patients with information about the long-term impact of their disease, suggest ways in which late effects may be prevented or reduced, and provide an indication about who would benefit from counselling.

Any conclusions about HRQoL are necessarily dependent on the quality of measures available. Measures can be evaluated on a number of criteria including: reliability (test-retest reliability and internal consistency), validity, and appropriateness for the population of interest [7]. Reliability is usually indicated by internal consistency or Cronbach's alpha, the extent to which the items of a scale assess the same concept. An internal consistency of 0.70 or above is generally considered to be acceptable [8]. Test-retest reliability is established when individuals complete a measure on two separate occasions and their scores are highly correlated.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Validity refers to the extent to which the measure reflects the construct of interest. It is generally assessed by comparison with similar measures and correlation with observable criteria. Finally, for this review, measures were considered appropriate for lymphoma survivors if they were either generic (applicable to anyone) or survivor-specific. Measures designed to assess HRQoL during initial treatment, with their emphasis on physical symptoms were not considered sensitive to the issues affecting survivors.

We therefore report a systematic review to determine HRQoL in survivors of HL or NHL. Our first aim was to identify and evaluate commonly used measures. In addition, we aimed to determine (i) HRQoL relative to the general population; (ii) associations between HRQoL and different treatments; and (iv) associations between HRQoL and demographic, medical and psychological variables.

Deleted:

## METHOD

The literature search aimed to identify any research study published in a peer reviewed journal that assessed HRQoL in survivors of lymphoma (HL or NHL) at least six months post treatment, using a standardized measure of HRQoL. Articles were excluded if they: (i) sampled childhood cancer survivors only; (ii) were case reports or reviews of previous literature; or (iii) did not report analyses by histological diagnosis.

Three methods were used to locate relevant studies: a keyword search, a backward search, and a manual search of relevant journals. First, the databases Medline, PsycInfo and Web of Knowledge were searched for articles published in the English language covering the period from January 1985 to April 2009. The search included the following terms: Hodgkin's disease, lymphoma (non-Hodgkins), and health-related quality of life. After each term was entered into the keyword function the cancer-related terms were combined using the OR function. This generated 32 hits from PsycInfo, 157 hits from Medline, and 456 hits from Web of Knowledge. After initial review of the abstracts those that did not meet the inclusion criteria were excluded. This resulted in identification of 36 articles as potentially eligible. Despite extensive searches, one article [9] could not be traced. Following the keyword search,

1  
2 we then carried out a backward search in which we located papers by examining the  
3 reference lists of all papers obtained from the first step. This identified nine further  
4 articles. Then, following a manual search of the journals 'Psycho-Oncology,'  
5 'European Journal of Cancer,' 'Journal of Clinical Oncology' and 'Quality of Life  
6 Research' for the period January 1985 to April 2009, one further article was  
7 identified. This resulted in a total of 45 articles that were obtained and examined  
8 against the inclusion and exclusion criteria.  
9  
10  
11  
12

## 13 RESULTS

### 14 Review of the articles

15  
16 Following detailed review of the articles against the inclusion/exclusion criteria, 18  
17 articles based on 15 data sets were retained. The following information was extracted  
18 from each study: aims, sample size by histological diagnosis (including percentage of  
19 men) and response rate, age, time since diagnosis, treatment, comparison group where  
20 applicable, measures and results. The studies were conducted in the US (n=4),  
21 Norway (n=3), the Netherlands (n=2), Israel, France, Spain, Sweden, Austria and  
22 Canada (1 each). All studies included demographic or medical variables as correlates  
23 of HRQoL.  
24  
25  
26  
27  
28  
29

### 30 Aim 1: Evaluation of Measures

31  
32 Five different measures of HRQoL were identified. These are summarized  
33 and assessed for reliability, validity and appropriateness for lymphoma survivors in  
34 Table I. We identified eight studies which utilised a generic measure (the SF-36  
35 health survey; [10]) to compare lymphoma survivors to the general population. The  
36 remaining measures were disease specific. These included three appropriate for  
37 assessment during treatment (EORTC QLQ-C30: [11]; FACT-An: [12]; CARES  
38 [Ganz et al., 1992][13]) and one designed for survivors (QoL-CS: [14] – two studies).  
39  
40  
41  
42  
43  
44  
45

### 46 Aim 2: HRQoL relative to the general population

47  
48 HRQoL was compared with that of the general population in ten articles that  
49 covered eight datasets. These articles are summarised in Table II. Eight articles  
50 covering six datasets [15, 17, 19-24] made these comparisons using the SF-36 health  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

survey [10]. In all eight [articles](#), lymphoma survivors reported worse physical functioning relative to the general population even when controlling for [symptoms of post-traumatic stress disorder \(PTSD\)](#) [15]. Lymphoma survivors also reported worse social functioning relative to the general population [19]. However, [the mental component summary \(which in the SF-36 includes emotional and social but not cognitive function\)](#) did not differ significantly from the general population in any of these eight studies, [although impaired functioning relative to controls was noted on some subscales](#) [19, 20]. [The mental component summary is more reliable and comprehensive than the subscales it comprises.](#)

Two additional [articles](#) [16, 18] [compared lymphoma survivors with the general population](#) using the EORTC QLQ-C30 (see Table II). Lymphoma survivors reported worse physical functioning than the general population [in both studies](#). In addition, [survivors](#) reported worse social functioning, more fatigue, more problems with physical role and cognitive functioning [18], and more dyspnoea (shortness of breath) [16, 18].

[Aim 3: Associations between treatments and HRQoL](#)

Deleted: ¶

[Details about associations between treatments and HRQoL are reported in Tables II and III.](#) [Lymphoma](#) survivors who had been treated by chemotherapy reported worse social well-being (as measured by the CS-QoL) and worse psychological well-being relative to [survivors](#) who had not had chemotherapy [22]. They also reported worse social and physical well-being, more fertility concerns, and greater influence of cancer and its treatment on employment relative to those who had had radiotherapy specific to the tumour site [25]. Those who had experienced mantle field radiation either alone or in combination with chemotherapy had more dyspnoea than those who had not [30]. Finally, survivors who had experienced combined modality therapy (chemotherapy plus radiotherapy) reported more deficits in physical functioning, dyspnoea, pain and fatigue than those who had been treated by either chemotherapy or radiotherapy alone [29].

However, the evidence above is based on studies with [heterogeneous](#) samples which precluded comparisons between chemotherapy regimens. A cross-sectional comparison of MOPP, ABVD and MOPP/ABVD chemotherapy demonstrated no differences in terms of effects on [physical and mental](#) HRQoL [16]. [Finally, a](#)



1  
2  
3 | randomised controlled trial in which patients were followed for two years [28]  
4 demonstrated no differences between subtotal lymphoid irradiation alone versus  
5  
6 | combined with doxorubicin and vinblastine chemotherapy in terms of effects on  
7 physical and psychosocial HRQoL.  
8  
9

10 | Aim 4: Associations between HRQoL and and demographic, medical and  
11 psychological variables  
12

#### 13 14 15 Demographics

16 | Although older age was associated with worse physical HRQoL [16, 18-19,  
17 22, 32], worse mental functioning was found for younger patients [29]. Men reported  
18 better role functioning [18], fewer role limitations [19] better physical functioning  
19 [16, 19] and better emotional functioning [19] than women. In contrast, one study  
20 found that men experienced greater fatigue and worse overall HRQoL than women  
21 [30]. Lower educational level was associated with worse HRQoL [18-19, 21].  
22 Finally, employed survivors reported better physical functioning than unemployed  
23 survivors [21, 32], as well as better emotional HRQoL and general health [21] and  
24 better vitality and mental functioning [22].  
25

#### 26 27 28 Medical variables

29  
30  
31 | More advanced disease was associated with worse HRQoL [24], but those  
32 who relapsed did not report worse HRQoL than those who remained disease-free [23].  
33 Better vitality, social functioning, emotional role and mental health were found for  
34 those 10-15 years post-diagnosis than those 5-9 years post-diagnosis [20, 22]. In  
35 contrast, Greil et al. [29], found no relation between time since treatment and any  
36 domains of HRQoL. The presence of co-morbid illnesses was associated with worse  
37 physical HRQoL [18, 21-22, 32].  
38  
39

#### 40 41 42 43 Psychosocial, lifestyle and other variables

44  
45 | More PTSD symptoms were associated with worse mental and physical  
46 functioning [15]. A lower sense of coherence (defined as the extent to which  
47 individuals believe their life to be comprehensible, meaningful and manageable) [33]  
48 was associated with worse HRQoL [24]. Financial problems were associated with  
49 worse mental functioning [24, 26]. Meeting public health guidelines for exercise was  
50 associated with better HRQoL in patients with NHL [27, 31]. This was a significant  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Deleted: ¶

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

dose-response relation, where HRQoL improved as exercise increased [27]. Patients experienced more dyspnoea if they were older, had a lower educational level and a history of medical complications [18]. Finally, sleep disturbance was associated with dyspnoea, fatigue, pain, financial difficulties and worse global HRQoL [30].

## DISCUSSION

In considering the HRQoL of survivors of lymphoma, we recognise first the importance of the specific measure of HRQoL adopted. All measures identified had acceptable reliability and validity (table 1). Three of the measures identified (the EORTC QLQ C-30 [11], the FACT [12] and the CARES [13] might be considered inappropriate for cancer survivors since they capture immediate effects of diagnosis and treatment rather than issues relating to re-integration and late effects [34]. Further, as a cancer-specific measure, the EORTC measure is inappropriate for use by general population controls. Despite this, two studies compared HRQoL between lymphoma patients and the general population using this measure. Thus, the conclusions should be treated with caution.

Most frequently, HRQoL was assessed using the SF-36 [10]. This is a generic measure, and therefore appropriate for comparison with the general population but does not address the specific problems experienced by cancer survivors. The only measure specifically developed for cancer survivors is the QoL-CS [14]. However, several issues have been identified with this measure: although it is intended for survivors longer than five years post diagnosis, validation was based on survivors 4-28 months post-diagnosis; several items assess distress at the time of diagnosis and treatment; and some items ask about change but fail to indicate direction (meaning that survivors with positive and negative responses would receive the same scores) [35]. Further, there are no disease-specific modules for survivors, even though some late effects differ as a function of cancer site.

In an attempt to address these issues, it has been recommended that studies should use two measures where possible: a survivor-specific measure to assess quality of life, and a generic measure [36-37]). Attention needs to be given to creating more sensitive measures of quality of life for cancer survivors, so that their problems can be documented and addressed appropriately (see also [38]).

1  
2  
3  
4 With these comments in mind, the evidence suggests that on average long-  
5 term survivors of lymphoma experience good overall mental HRQoL relative to the  
6 general population, although some medical and demographic variables constitute risk  
7 factors. Where there are concerns that mental HRQoL is severely compromised, it is  
8 important to supplement HRQoL measures with more established measures of  
9 emotional functioning or psychiatric assessment. In contrast, long-term survivors of  
10 lymphoma report poorer physical HRQoL relative to matched controls, suggesting  
11 that diagnosis and treatment impact more on physical than mental health in the long  
12 term. Although poorer physical HRQoL relative to the general population might be  
13 expected given the incidence of late medical complications and fatigue in lymphoma  
14 survivors [39], it is also possible that current measures provide more sensitive  
15 assessment of physical than mental HRQoL.

16  
17  
18  
19  
20  
21  
22  
23  
24 There is some evidence that HRQoL in the first two years after diagnosis does  
25 not differ depending on the specific treatment [28]. However, the participants in this  
26 study were younger than the general population with lymphoma. Since many late  
27 effects are not apparent until several years after treatment, more long-term follow up  
28 studies are required to compare the relative side-effects of different treatment  
29 regimens. We found some evidence that chemotherapy is associated with worse  
30 social HRQoL relative to other treatments [22, 25]. Chemotherapy often leads to  
31 fatigue [40], which may account for this finding. However, patients with advanced  
32 stage disease are also more likely to be treated with chemotherapy, meaning that the  
33 effect of treatment may be confounded by stage [25].

34  
35  
36  
37  
38  
39  
40 The relation between older age and worse physical HRQoL was expected, and  
41 can be explained in several ways. First, older people are more likely to suffer from  
42 co-morbid illnesses. Second, some late effects are more likely to occur as time since  
43 treatment (and therefore age) increases [4]. Furthermore, physical health tends to  
44 decline with age for the general population.

45  
46  
47  
48  
49 Lower educational level was associated with worse HRQoL in three studies.  
50 Lower socioeconomic status has been associated with a less healthy lifestyle in  
51 general [41] which may be reflected in poorer HRQoL, probably because those with  
52  
53  
54

1  
2 lower educational qualifications are also likely to be lower earners. Such patients are  
3 more likely to be employed in manual work, and consequently may have to take more  
4 time off work following completion of treatment, leading to constraints in their  
5 financial circumstances, which have been associated with worse mental health [25].  
6  
7 In support of this idea, unemployment was associated with worse physical HRQoL  
8  
9 [21].  
10  
11

12  
13 Survivors who reported meeting public health exercise guidelines (150  
14 minutes of moderate intensity activity per week) also reported better HRQoL [27, 31].  
15 This relation held after controlling for age, gender, employment status, time since  
16 diagnosis and co-morbid conditions. Although patients in better health may be able to  
17 exercise more, this evidence suggests that advice to take as much exercise as is  
18 feasible is potentially valuable.  
19  
20  
21  
22

23  
24 The relation between psychological variables and HRQoL was assessed in  
25 only two studies [15, 24]. Associations between psychological variables and HRQoL  
26 might suggest ways to improve guidelines for appropriate referral to psychological  
27 services. Appropriate treatment for psychological issues would be likely to facilitate  
28 survivors' attainment of the best HRQoL possible. However, in order to facilitate  
29 this, psychological issues should be assessed at follow-up. This is particularly  
30 important as psychological late effects of treatment are often not documented in  
31 medical notes [42] and thus may not be addressed by clinicians.  
32  
33  
34  
35

36  
37 A number of limitations with current methodology can be identified. Only  
38 nine of the studies utilised research designs which were longitudinal or case-control.  
39 Longitudinal studies are essential to understand changes in HRQoL over time. Case-  
40 control studies facilitate judgement about whether HRQoL is really compromised  
41 relative to age-matched controls from the general population, and may provide greater  
42 accuracy than population norms.  
43  
44  
45  
46

47  
48 More detailed description is required regarding sample demographics. First,  
49 results were not analysed by gender although three studies [18-19, 30] suggested  
50 gender differences in HRQoL. Identification of gender differences may aid clinicians  
51 in deciding what aspects of HRQoL to assess in patients, and facilitate identification  
52  
53  
54

1  
2 of correlates of HRQoL. Second, as a minimum, information is needed on  
3 socioeconomic status (assessed by more than one method where possible) and marital  
4 status. Third, studies should differentiate between survivors younger than 45 and  
5 older patients, as younger patients may have qualitatively different concerns [43].  
6  
7

8  
9  
10 More detailed reporting of descriptive statistics is also required. Many studies  
11 failed to report means and standard deviations. These enable comparison between  
12 studies, and are necessary for calculating effect sizes in meta-analysis [44].  
13 Particularly where research is based on small samples from specific treatment centres,  
14 meta-analyses may be the only way to obtain information based on larger samples,  
15 and thus identify common trends across regions and cultures. They also enable  
16 assessment of individual predictors of HRQoL such as personality or demographic  
17 factors.  
18  
19  
20  
21  
22

23  
24 Serious attention should be paid to creating well-designed studies that include  
25 matched controls, and using measures that assess the full range of problems  
26 experienced by lymphoma survivors, including disease-specific modules where  
27 possible. Also, analyses should be carried out by gender in order to further  
28 understanding of demographic, medical and psychosocial correlates of HRQoL in  
29 survivors of lymphoma. This would enable clinicians to provide patients with better  
30 advice about the late effects of their disease, and suggest ways in which these effects  
31 may be prevented or mitigated.  
32  
33  
34  
35  
36

37  
38 Due to the methodological issues underlying research into HRQoL following  
39 lymphoma, only limited conclusions can be drawn. However, this review has clearly  
40 identified pathways and recommended standards for future research. In conclusion,  
41 we note the progress made in treatment of lymphomas, as demonstrated in the  
42 increasing numbers of survivors. Comparable progress is now needed to determine  
43 the range, severity and prevalence of untoward consequences of lymphoma and its  
44 treatment, and how to mitigate those consequences.  
45  
46  
47  
48

#### 49 ACKNOWLEDGMENTS

50  
51 This research was made possible by grant C481/A8141 awarded by Cancer  
52 Research UK to C Eiser and A Pacey.  
53  
54

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

## References

1. [Boyle P, Levin B. World Cancer Report 2008. Lyon, France: IARC Press; 2009.](#)
2. Office for National Statistics. One- and five-year survival (%) for adult patients diagnosed during 1998-2001, 21 common cancers, by sex and age, England. 2005; <http://www.statistics.gov.uk/StatBase/Product.asp?vlnk=14007>
3. Office for National Statistics. Cancer statistics registrations: registrations of cancer diagnosed in 2006, England. 2009; <http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843>
4. [Ng AK, Mauch PM. Late effects of Hodgkin's Disease and its treatment. Cancer Journal 2009; 15: 164-168.](#)
5. [Cella, DF \(1995\). Measuring quality of life in palliative care. Seminars in Oncology 1995; 22: 73-78.](#)
6. Soni MK, Cella D. Quality of life and symptom measures in oncology: an overview. American Journal of Managed Care 2002; 8: S560-S573.
7. [Eiser C, Morse R. Quality of life measures in chronic disease in childhood. Health Technology Assessment 2001; 5 \(4\).](#)
8. [Cronbach LJ. Coefficient alpha and the structure of tests. Psychometrika 1951; 16: 297-334.](#)
9. [Beser NG, Oz F. Quality of life in lymphoma patients. Clinical Excellence for Nurse Practitioners; 9: 153-161.](#)
10. Ware JE, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Lincoln, RI: QualityMetric Incorporated, 2000
11. Aaronson NK, Ahmedzai S, Bergman B et al. for the European Organization for Research and Treatment of Cancer Study Group on Quality of Life. The European Organization for Research and Treatment of Cancer QLQ-C30. A quality of life instrument for use in international clinical trials in oncology. Journal of the National Cancer Institute 1993; 85: 365-376.
12. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue. Seminars in Hematology 1997; 34: 13-19.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
13. [Ganz PA, Schag CA, Lee JJ, et al. The CARES: A generic measure of health-related quality of life for patients with cancer. \*Quality of Life Research\* 1992; 1: 19-29.](#)
  14. Ferrell BR, Dow KH, Grant M. Measurement of the quality of life in cancer survivors. *Quality of Life Research* 1995; 4: 523-531.
  15. Geffen DB, Blaustein A, Amir M, Cohen Y. Post-traumatic stress disorder and quality of life in long-term survivors of Hodgkin's Disease and Non-Hodgkin's Lymphoma in Israel. *Leukemia and Lymphoma* 2003; 44: 1925-1929.
  16. Gil-Fernandez JJ, Ramos C, Tamayo AT, et al. Quality of life and psychological well-being in Spanish long-term survivors of Hodgkin's disease: results of a controlled pilot study. *Annals of Hematology* 2003; 82: 14-18.
  17. Hjermstad MJ, Oldervoll L, Fossa SD, Holte H, Jacobsen AB, Loge JH. Quality of life in long-term Hodgkin's disease survivors with chronic fatigue. *European Journal of Cancer* 2006; 42: 327-333.
  18. Joly F, Henry-Amar M, Arveux P, et al. Late psychosocial sequelae in Hodgkin's Disease survivors: a French population-based case-control study. *Journal of Clinical Oncology* 1996; 14: 2444-2453.
  19. Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Reduced health-related quality of life among Hodgkin's disease survivors: A comparative study with general population norms. *Annals of Oncology* 1999; 10: 71-77.
  20. Mols F, Vingerhoets AJJM, Coebergh JW, et al. Better quality of life among 10-15 year survivors of Hodgkin's lymphoma compared to 5-9 year survivors: A population-based study. *European Journal of Cancer* 2006; 42: 2794-2801.
  21. Mols F, Coebergh JWW, van de Poll-Franse LV. Health-related quality of life and health care utilisation among older long-term cancer survivors: A population-based study. *European Journal of Cancer* 2007; 43: 2211-2221.
  22. Mols F, Aaronson NK, Vingerhoets AJJM, et al. Quality of life among long-term Non-Hodgkin Lymphoma survivors: A population-based study. *Cancer* 2007; 109: 1659-1667.
  23. van Tulder MW, Aaronson NK, Bruning PF. The quality of life of long-term survivors of Hodgkin's disease. *Annals of Oncology* 1994; 5: 153-158.
  24. Wettergren L, Bjorkholm M, Axdorph U, Langius-Eklöf A. Determinants of health-related quality of life in long-term survivors of Hodgkin's lymphoma. *Quality of Life Research* 2004; 13: 1369-1379.



- 1  
2  
3 | 25. Ahles TA, Saykin AJ, Furstenberg CT, et al. Quality of life of long-term  
4 survivors of breast cancer and lymphoma treated with standard-dose  
5 chemotherapy or local therapy. *Journal of Clinical Oncology* 2005; 23: 4399-  
6 4405.  
7  
8 | 26. Bellizzi KM, Farmer Miller M, Arora NK, Rowland JH. Positive and negative life  
9 changes experienced by survivors of Non-Hodgkin's Lymphoma. *Annals of*  
10 *Behavioral Medicine* 2007; 34: 188-199.  
11  
12 | 27. Bellizzi KM, Rowland JH, Arora NK, Hamilton AS, Farmer Miller M, Aziz NM.  
13 Physical activity and quality of life in adult survivors of Non-Hodgkin's  
14 Lymphoma. *Journal of Clinical Oncology* 2009; 27: 960-966.  
15  
16 | 28. Ganz PA, Moinpour CM, Pauler DK, et al. Health status and quality of life in  
17 patients with early-stage Hodgkin's disease treated on Southwest Oncology Group  
18 Study 9133. *Journal of Clinical Oncology* 2003; 21: 3512-3519.  
19  
20 | 29. Greil R, Holzner B, Kemmler G, et al. Retrospective assessment of quality of life  
21 and treatment outcome in patients with Hodgkin's Disease from 1969 to 1994.  
22 *European Journal of Cancer* 1999; 35: 698-706.  
23  
24 | 30. Norum J, Wist EA. Quality of life in survivors of Hodgkin's disease. *Quality of*  
25 *Life Research* 1996; 5: 367-374.  
26  
27 | 31. Vallance JKH, Courneya KS, Jones LW, Reiman T. Differences in quality of life  
28 between Non-Hodgkin's Lymphoma survivors meeting and not meeting public  
29 health exercise guidelines. *Psycho-Oncology* 2005; 14: 979-991.  
30  
31 | 32. Zebrack BJ, Yi J, Petersen L, Ganz PA. The impact of cancer and quality of life  
32 for long-term survivors. *Psycho-Oncology* 2008; 17: 891-900.  
33  
34 33. Antonovsky, A. *Unravelling the mystery of health: How people manage stress and*  
35 *stay well*. San Francisco: Jossey-Bass, 1987.  
36  
37 | 34. Gotay CC, Muraoka MY. Quality of life in long-term survivors of adult-onset  
38 cancers. *Journal of the National Cancer Institute* 1998; 90: 656-667.  
39  
40 | 35. Avis NE, Smith, KW, McGraw S, Smith RG, Petronis VM, Carver CS. Assessing  
41 Quality of Life in Adult Cancer Survivors (QLACS). *Quality of Life Research*  
42 2005; 14: 1007-1023.  
43  
44 | 36. Eiser C, Jenney M. Measuring quality of life. *Archives of Disease in Childhood*  
45 2007; 92: 348-350.  
46  
47 | 37. Krahn M, Bremner KE, Tomlinson G, Ritvo P, Irvine J, Naglie G. Responsiveness  
48 of disease-specific and generic utility instruments in prostate cancer patients.  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- Quality of Life Research 2007; 16: 509-522.
- | [38.](#) Pearce NJM, Sanson-Fisher R, Campbell HS. Measuring quality of life in cancer survivors: a methodological review of existing scales. *Psycho-Oncology* 2008; 17: 629-640.
- | [39.](#) Ruffer JU, Flechtner H, Tralls P, et al. Fatigue in long-term survivors of Hodgkin's lymphoma, a report from the German Hodgkin Lymphoma Study Group (GHSG). *European Journal of Cancer* 2003; 39: 2179-2186.
- | [40.](#) Smets EMA, Garssen B, Schusteruitterhoeve ALJ, Dehaes JCJM. Fatigue in cancer patients. *British Journal of Cancer* 1993; 68: 220-224.
- | [41.](#) Schnohr C, Hojbjerg L, Riegels M, et al. Does educational level influence the effects of smoking, alcohol, physical activity and obesity on mortality? A prospective population study. *Scandinavian Journal of Public Health* 2004; 32: 250-256.
- | [42.](#) Eiser C, Taylor N, Absolom K, Michel G. Under-diagnosis of morbidity in survivors of childhood cancer: Implications for follow-up care. [abstract]. *Psychology & Health*. 2009; 24 S1: 32.
- | [43.](#) Eiser C, Penn A, Katz E, Barr R. Psychosocial issues and quality of life. *Seminars in Oncology* 2009; 36: 275-280.
44. Glass G. Integrating findings: The meta-analysis of research. *Review of Research in Education*, 1977; 5: 351-379.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

**Table I: Description of measures used**

Scale	Subscales	Reliability	Validity	Type of measure
SF-36 [8] (Ware et al., 2002)	Physical component summary (physical functioning, role limitations due to physical problems, bodily pain, general health) Mental component summary (social functioning, role limitations due to emotional problems, vitality, mental health)	<u>Test-retest;</u> <u><math>\alpha &gt; 0.70</math></u>	<u>Correlates with observable physical</u> <u>outcomes</u>	Generic
EORTC QLQ-C30 [9] (Aaronson et al., 1993)	Physical, Role, Emotional, Cognitive and Social functioning, Global health status, Physical symptoms (fatigue, nausea and vomiting, pain, dyspnoea, sleep disturbance, appetite loss, constipation, diarrhoea)	<u>Test-retest;</u> <u><math>\alpha &gt; 0.70</math></u>	<u>Distinguishes patients with different</u> <u>performance status</u>	Cancer-specific; <u>appropriate</u> <u>during</u> <u>treatment</u>
FACT-An [10] (Cella et al., 1997)	Physical, Functional, Emotional, Social well-being, Anaemia symptoms	<u>Test-retest;</u> <u><math>\alpha &gt; 0.70</math></u>	<u>Discriminates based on medical</u> <u>variables; correlated with appropriate</u> <u>scales</u>	Cancer-specific; <u>appropriate</u> <u>during</u> <u>treatment</u>

CARES (Ganz et al., 1992)	Physical, psychosocial, marital, medical interaction, sexual	<u>Test-retest; <math>\alpha &gt; 0.70</math></u>	<u>Comprehensive; correlates with appropriate scales</u>	Cancer-specific; <u>appropriate during treatment</u>
QoL-CS [11] (Ferrell et al., 1995)	Physical, Psychological, Social, Spiritual well-being	<u>Test-retest; <math>\alpha &gt; 0.70</math></u>	<u>Correlates with appropriate scales, discriminates based on demographic and medical variables</u>	Cancer-specific: survivors

Table II: Correlates of quality of life: studies with comparison group

Study and country of origin	Aims	Sample (response rate)	Age (Mean, range) [SD]	Time since diagnosis (Mean, range) (years)	Treatment (n)	Comparison Group (n)	Measures	Findings
1. Geffen et al. (2003) [12] <a href="#">Israel</a>	1. Assess frequency of PTSD and PTSD symptoms relative to controls 2. Explore relation between PTSD and HRQoL	44 (96%): 36 HL, 8 NHL (46% men)	51 (27-80)	7.9 (2-16) all 2 yrs + since treatment	RT: 6 CT: 24 Both: 14	44 matched controls (sex, marital status, education, age) experienced traumatic event	SF-36	1) Lower physical HRQoL than controls, even after controlling for PTSD symptoms 2) Higher intensity PTSD a/w lower HRQoL
2. Gil-Fernandez et al. (2003) [13] <a href="#">Spain</a>	1. Assess HRQoL and psychological well-being of Spanish survivors	46 (68.6%) 32 men	43 (15-80)	7.6 (0.8-22.1)	RT: 7 CT: 10 Both: 29	46 GP, matched for age, sex, social status	EORTC QLQ-C30	1) Worse physical function, family relationships, more dyspnoea and economic difficulties than general population 2) Women worse physical HRQoL than men
3. Hjermstad et al. (2006) [14] <a href="#">Norway</a>	1. Assess HRQoL in survivors with chronic fatigue	475 HL (80%) 56% men	46 (21-74)	195 (53-431) months	RT/CT	GP (2141), same age range as patients, adjusted for sex, educational level	SF-36	1) Lower physical HRQoL than general population, chronic fatigue 3x higher

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

4. Joly et al. (1996) [15] <a href="#">France</a>	1. Determine type and frequency of psychosocial problems in French long-term survivors relative to controls	93 HL (91%) Numbers of each gender not reported separately for patients and controls	42 (23-85)	10 (4-17)	RT: 34% CT: 4% Both: 62% MOPP: 74% ABVD: 16% Both: 10%	186 GP, matched for age, sex, city of residence	EORTC QLQ-C30	1) Lower physical, role cognitive and social functioning, more dyspnoea, fatigue than general population 2) Men better role functioning than women 3) Lower educational level: worse physical, role functioning, more dyspnoea 4) Medical complications: more dyspnoea, lower physical, role and cognitive function
5. Loge et al. (1999) [16] <a href="#">Norway</a>	1. Compare HRQoL with norms from general population 2. Determine disease or treatment factors affecting HRQoL	459 HL (82%) 56% men	44 [11.8]	12.2 (3-23)	RT: 174 CT: 66 Both: 217 RT: 76% mantle field LVPP: 54% ABOD: 46%	As for 3	SF-36	1) ) Lower vitality, general health, physical functioning, role physical, social functioning than general population 2) Men better role physical, physical functioning, role emotional than women 3) More education: better physical HRQoL
6. Mols et al.* (2006) [17] <a href="#">Netherlands</a>	1. Examine differences between survivors and age-matched controls 2. Compare HRQoL of 5-9 years and 10-15 years survivors	132 NHL (80%) Gender not reported	20-34; 35-49;50+	48: 5-9 yrs 68: 10-15 yrs	RT: 25 CT: 38 Both: 66	Age-matched GP (1771)	SF-36; QOL-CS	1) 5-9 yrs: lower general health, social functioning, mental health 2) 10-15yrs: lower general health than controls, but higher physical functioning 3) 10-15 years: higher HRQoL than 5-9yrs survivors: vitality, social functioning, role emotional, mental health

Deleted: ¶

1									
2									
3	7. Mols et al.	1. Compare HRQoL with	155 NHL	70	Not reported	Surgery: 22	As 6	SF-36	1) Younger: lower vitality, general
4	(2007a) * [18]	general population	survivors		by disease	RT: 85			health, but less pain
5	<a href="#">Netherlands</a>	2. Compare survivors	(80% of full			CT: 115			2) Co-morbidity: worse social
6		over and under 70	sample)			Surveillance:			function, physical health, role
7			54% male			12			emotional,
8						Combinations			3) More education: better physical
9						not reported			function
10									4) Employed: better role physical,
11									role emotional, general health
12	8. Mols et al.	1. Investigate association	221 NHL	55.3	5-9 yrs: 145	RT: 33	As 6	SF-36;	1) Chemo: lower social and
13	(2007b)* [19]	of demographic and	survivors		months	CT: 82		QOL-CS	psychological well-being
14	<a href="#">Netherlands</a>	clinical factors with	(82%)		10-15yrs: 76	Both: 58			2) Older age: lower physical
15		HRQoL	51% male		months	Also surgery:			functioning
16		2. Compare HRQoL to				28			3) Co-morbid conditions: poorer
17		general population				Wait: 20			physical functioning, more pain
18									4) Employed: better vitality, mental
19									health
20									5) Longer since diagnosis: better
21									social well-being (QoL-CS)
22	9. Van Tulder et	1. Examine HRQoL,	81 HL(92%)	43.6 (25-77)	14 (2.0)	All: mantle	114 age-matched	SF-36	1) Lower physical functioning, role
23	al. (1994) [20]	prevalence, severity of	42 male			field radiation	healthy hospital		physical, general health than
24	<a href="#">Netherlands</a>	psychosocial problems in				CT: 19	visitors		controls
25		long-term survivors				Vinblastine: 5			
26									
27	10. Wettergren et	1. Evaluate HRQoL in	121 (62%)	47 (23-75)	13 (6-24)	MOPP: 14	236 GP (stratified by	SF-12	1) Poorer physical health than
28	al. (2004) [21]	long-term HL survivors	55% male			RT: 55	age and sex)		controls
29	<a href="#">Sweden</a>	2. Identify determinants				CT:28			2) More advanced disease: more
30		of HRQoL				Both: 17			disease-related problems
31									3) Lower sense of coherence: worse
32									HRQoL

Glossary: SF-36: Short Form-36 health survey; RT – Radiotherapy; CT – chemotherapy; EORTC QLQ-C30: European Organization for Research and Treatment of Cancer

Quality of Life Questionnaire; GP – general population; QOL-CS: Quality of Life-Cancer Survivors; MOPP – Mechlorethamine, vincristine, procarbazine, prednisone;

ABVD – Doxorubicin, bleomycin, vinblastine, dacarbazine; LVPP – Chlorambucil, vinblastine, procarbazine, prednisone; ABOD – doxorubicin, bleomycin, vincristine,

dacarbazine

\* These studies are drawn from the same population

Table III: Correlates of quality of life: [studies without comparison group](#)

Study	Aims	Sample (response rate)	Age (Mean, range) [SD]	Time since diagnosis (years) (Mean, range) [SD]	Treatment	Measures	Findings
1. Ahles et al. (2005) [22] <a href="#">USA</a>	1. Compare QoL of long-term survivors of lymphoma treated with chemotherapy or <a href="#">surgery</a>	103 (76% overall) Chemo: 45% male <a href="#">Surgery</a> : 48.7% male	Chemo: 55.8 [13.5] <a href="#">Surgery</a> : 50.4 (12.8)	10.0 [5.3]	CT: 66 <a href="#">Surgery</a> : 37	QOL-CS	1) Chemo: worse social and physical QoL – more fatigue, aches and pains, worse overall health 2) Chemo: more fertility concerns, greater interference of cancer and treatment on employment
2. Bellizzi et al. (2007)* [23] <a href="#">USA</a>	1. Describe association between demographic, disease-related and psychosocial factors, and positive and negative life change	NHL 308 (72.5%) 51.3% male	60 (23-85)	3.5 [0.1]	CT: 94.2%	SF-36	1) Increase in negative life change: decline in physical and mental functioning
3. Bellizzi et al. (2009)* [24] <a href="#">USA</a>	1. Examine demographic, disease-related and cognitive factors a/w physical activity in NHL survivors 2. Explore relation between physical activity and HRQoL	NHL 319 (72.5%) 51.3% male	59.8 (14.8)	2-5.9 (3 groups)	CT: 156 CT+ RT: 108 Transplant: 34	SF-36	1) Met guidelines for exercise or some activity: better mental and physical health than if sedentary, significant dose-response pattern 2) Similar results - anxiety and depression 3) 25% 1 SD below norm – mental health, 1.5 SDs below norm – physical health
4. Ganz et al. (2003) [25] <a href="#">USA</a>	1. Examine outcomes during first two years after assignment to STLI or CMT in SWOG trial	Baseline 237 (97%) 60% male 2 yrs: 160 (70%)	Radiation: 31.4 (17-85) Combined: 33.7 (17-71)	Recruited at diagnosis, 2 yr follow-up	At 2yrs STLI: 78 STLI+CMT: 82	CARES-SF; SF-36 vitality, general health	1) No differences between radiation and combination therapy at 2 years <a href="#">in terms of effects on HRQoL, vitality</a> 2) Physical, psychosocial, sexual, marital and medical interaction returned to baseline 2) General health worse at 2 years
5. Greil et al. (1999) [26] <a href="#">Austria</a>	1. Assess QoL in HD survivors 2. Investigate impact of different treatment modalities on QoL	HD 126 (64.9%) 99/225 male (44%)	36.9 (6-89) at diagnosis	10.5 (0.9-34.0)	CT: 63 RT: 70 Both: 92	EORTC QLQ-C30	1) More deficits in physical function, dyspnoea, pain, & fatigue if combined modality therapy




6. Norum & Wist (1996) [27] <a href="#">Norway</a>	1. Document QoL in HLsurvivors 2. Determine whether mantle field irradiation causes reduced QoL 3. Determine whether QoL differs by gender	HL 42 (86%) 24 male	Not reported	Not reported	RT: 10 CT: 16 Both: 16	EORTC QLQ C-30	1) Mantle field radiation: dyspnoea 2) Males greater fatigue, lower HRQoL 3) Sleep disturbance: fatigue, pain, financial difficulties, dyspnoea, worse HRQoL 4) Physical condition/ medical treatment caused financial difficulties in 45%
7. Vallance et al. (2005) [28] <a href="#">Canada</a>	1. Examine HRQoL differences between NHL survivors meeting and not meeting exercise guidelines	NHL 438 (62%) 51.6% male	61.1 [13.1]	62 [25.3] (months)	CT: 64.6% CT+RT: 15.5% Wait: 17.1%	FACT-An	1) Meeting exercise guidelines (150 minutes/ week): better physical, emotional and functional HRQoL
8. Zebrack et al. (2008) [29] <a href="#">USA</a>	1. Examine relation between perceptions of impact of cancer and HRQoL, across cancers, after controlling for medical and socio-demographic factors	193 (33%) 49 HL/NHL 56% male (overall)	61.5 [14.3]Whole sample	7.7 [1.9]	Not reported	SF-36 QOL-CS	1) Fewer co-morbidities: better physical health, HRQoL 2) Younger age: better physical health, but worse mental health, overall HRQoL 3) Employed: better physical health

Glossary: QOL-CS – Quality of Life – Cancer Survivors; CT – chemotherapy; RT – radiotherapy; SF-36 – Short Form 36 health survey; STLI – subtotal lymphoid irradiation; CMT – combined modality therapy; CARES-SF – Cancer Rehabilitation Evaluation System – Short Form; EORTC QLQ-C30 : European Organization for Research and Treatment of Cancer Quality of Life Questionnaire; FACT-An – Functional Assessment of Cancer Therapy – Anaemia

\*These studies are drawn from the same population

Figure 1: Search process



**Figure II: Summary of Findings and Recommendations for Future Research****Measures**

- Measures designed for use during treatment used on long-term cancer survivors

**Recommendation:**

- Studies should utilise a survivor-specific and a generic measure of HRQoL

**Correlates of HRQoL**

- Lymphoma survivors have poor physical HRQoL, but mental HRQoL equivalent to general population on average
- **Correlates** of better physical HRQoL: younger age, higher educational level, following exercise guidelines
- Insufficient evidence to determine:
  - 1) Effects of treatment on HRQoL
  - 2) Relation between psychological factors and HRQoL

**Recommendations for future research:**

- Use of longitudinal designs
- Detailed reporting of demographics and descriptive statistics